Bedside Bike Early Mobilization Program for Inpatients (BB-STEP)

March 24, 2026 updated by: Babar Khan, MD, MS, Indiana University
Hospital immobility leads to serious complications including muscle loss, weakness, delirium, pressure ulcers, and blood clots. Despite being medically stable, hospitalized patients spend over 90% of their time in bed due to staffing shortages, fall risks, and limited physical therapy availability. Within one week of admission, patients can lose approximately 2% of thigh muscle mass per day, and nearly half develop clinically significant hospital-acquired weakness.The Bedside Bike is a portable, low-resistance exercise device that clamps securely to hospital beds, allowing patients to perform leg and arm cycling exercises safely without leaving their bed. This study will evaluate whether hospitalized patients at Indiana University Health facilities can feasibly and safely use the Bedside Bike to maintain mobility during their hospital stay.This quality improvement study will enroll 80 adult inpatients expected to stay at least 3 days. All participants will receive the Bedside Bike in addition to usual care (standard physical therapy and medical treatment). The study will measure how often patients use the device, whether it is safe (tracking any device-related problems), and whether it may help improve outcomes such as hospital length of stay, functional mobility scores, discharge to home, and rates of hospital-acquired weakness. Participants will have functional assessments at admission and discharge, use the Bedside Bike throughout their hospitalization (targeting at least 15 minutes daily), and be followed for 60 days after discharge to track readmissions, falls, living arrangements, and mortality.

Study Overview

Detailed Description

Background and Rationale:

Immobility during hospitalization is a widespread and often preventable cause of disability, particularly among older adults and patients recovering from critical illness. Research demonstrates that very modest activity confers significant benefits: walking just 275 steps per day reduces 30-day readmissions by 10% in older inpatients, and a single 20-minute cycling session on weekdays shortens length of stay and improves functional recovery in ventilated ICU patients. However, most patients remain largely immobile despite being physiologically capable of low-intensity exercise.

The Bedside Bike addresses key barriers to inpatient mobility by eliminating the need to transfer out of bed (reducing fall risk), requiring less than 1 minute of staff setup time (addressing staffing constraints), providing adjustable resistance for progressive exercise, and allowing patients to exercise independently without navigating hallways with IV lines and catheters. The device is FDA-cleared (Class I, product code ION, 21 CFR §890.5370) and has been tested with healthcare providers and healthy volunteers without safety concerns.

Study Design and Implementation:

This is a prospective, single-arm quality improvement implementation study conducted across three Indiana University Health hospital units: IU Methodist Post-ICU step-down unit, IU Bloomington ortho/neuro and medical/surgical units, and IU North medical/surgical unit. The study uses a pragmatic design embedded within routine clinical care, with contemporaneous historical unit-level metrics from 2025 serving as comparison benchmarks.

Device Setup and Operation:

After informed consent, the Bedside Bike is installed at the bedside and patients receive training on its use. The device clamps securely to the bed frame with pedals positioned approximately 10 cm above the mattress. Patients can adjust resistance via a dial and exercise at their own pace, targeting at least one 15-minute session daily. A quick-release lever allows the device to be disengaged in under 2 seconds if needed for patient transfers or clinical procedures.

The Bedside Bike includes a Bluetooth-enabled telemetry module that automatically records exercise metrics including duration, revolutions per minute, and resistance level. Data is encrypted and uploaded nightly to a secure REDCap database at Indiana University. Between patients, the device is cleaned with standard hospital disinfectant, and Clinical Engineering performs weekly quality assurance checks.

Integration with Standard Care:

Patients continue all standard medical care without restrictions. Physical therapy, occupational therapy, and progressive ambulation programs proceed as usual. The Bedside Bike is designed to augment-not replace-skilled therapy sessions. There are no restrictions on pain medications, sleep aids, or nutritional support. Cycling is temporarily paused during hemodialysis or when telemetry alarms require clinical attention.

Data Safety Monitoring:

The Principal Investigator leads weekly data safety monitoring huddles to review enrollment progress, device utilization patterns, and adverse events. Any unanticipated serious adverse event triggers immediate IRB notification within 48 hours. The study protocol includes automatic pause criteria: enrollment halts if any device-related serious adverse event occurs or if feasibility drops below 40% for two consecutive weeks, pending comprehensive safety review.

Duration and Follow-up:

The enrollment period spans 3 months (February through April 2026) with approximately 16 patients enrolled monthly across all sites. Each participant is followed through hospital discharge plus 60 days post-discharge. The final 60-day follow-up is completed by the end of June 2026, with database lock and analysis extending through September 2026.

Statistical Design:

With N=80 participants, the study provides 90% power (α=0.05, two-tailed, assuming SD of 2 days) to detect a clinically meaningful 0.2-day reduction in length of stay compared to historical unit averages. This sample size accounts for potential dropouts and incomplete data. Missing data under 5% will be handled using multiple imputation (m=5 iterations); higher rates of missingness will default to complete-case analysis.

This pragmatic feasibility study will provide critical data on device utilization, safety profile, and preliminary effectiveness signals to inform the design of larger randomized controlled trials and guide clinical implementation strategies for in-bed cycling technology across diverse inpatient populations.

Study Type

Interventional

Enrollment (Estimated)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Theresa Joyce
  • Phone Number: 317-278-1882
  • Email: tajoyce@iu.edu

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Age 18 years or older
  • Admitted to participating hospital unit within 24 hours or less
  • Expected hospital stay of at least 3 days
  • Able to follow one-step commands
  • Anti-gravity leg strength
  • Informed consent obtained from patient or legally authorized representative

Exclusion Criteria:

  • Hemodynamic instability requiring vasopressor support with systolic blood pressure <90 mmHg
  • Requiring fraction of inspired oxygen (FiO₂) >0.6 or positive end-expiratory pressure (PEEP) >8 cm H₂O
  • Uncontrolled cardiac arrhythmia
  • Open lower extremity wounds within the pedal arc area
  • Lower limb fracture requiring traction or immobilization
  • Active deep vein thrombosis (DVT) without therapeutic anticoagulation
  • Body mass index (BMI) >45 kg/m² (exceeds device reach limit)
  • Current pregnancy
  • Concurrent enrollment in another interventional clinical trial that would conflict with study procedures or outcomes

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention Group (receiving Bedside Bike + Usual Care)
All enrolled participants receive the Bedside Bike device plus standard hospital care. Installed within 24 hours of admission, patients are trained on device operation and safety. Setup takes <1 minute. Patients use the device daily throughout hospitalization, targeting ≥15 minutes per session. Exercise is self-paced with adjustable resistance via patient-controlled dial. Recumbent (in-bed) cycling allows unsupervised, patient-initiated use without staff presence. Average duration is 5-7 days (enrollment to discharge). Participants continue all standard care including physical/occupational therapy, ambulation, medications, and nutrition.
The Bedside Bike is a Class I medical device (21 CFR §890.5370, product code ION) featuring a magnetic resistance mechanism powering arm and leg pedal systems with a universal clamp for standard hospital bed frames. Key safety features include smooth surfaces without sharp edges, immediate stop mechanism with no momentum carry-over, cushioned pedals supporting single-pedal operation for hemiparesis, self-retracting tether cable preventing entanglement, battery-powered operation eliminating tripping hazards, nearly silent operation, lightweight construction, and soft-start/soft-stop resistance adjustment.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Device Utilization Feasibility
Time Frame: First 5 hospital days (or until discharge if sooner)
Percentage of enrolled participants who achieve at least 75 cumulative minutes of Bedside Bike use during their first 5 hospital days. Success criterion: ≥80% of participants meet this threshold.
First 5 hospital days (or until discharge if sooner)
Incidence of Device-Related Adverse Events
Time Frame: From enrollment through hospital discharge, approximately 5-7 days on average
Rate of device-related adverse events (AEs) and serious adverse events (SAEs). Safety success criteria: zero device-related SAEs and ≤5% rate of minor device-related AEs. Device-related events are defined as any adverse outcome directly attributable to the Bedside Bike device itself or its use.
From enrollment through hospital discharge, approximately 5-7 days on average
Hospital Length of Stay
Time Frame: From hospital admission to discharge, approximately 5-7 days on average
Duration of index hospitalization in days, compared to 2025 unit-specific median length of stay. Target: reduction of ≥0.2 days versus historical benchmark.
From hospital admission to discharge, approximately 5-7 days on average

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in AM-PAC 6-Clicks Mobility Score
Time Frame: Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
Change in Activity Measure for Post-Acute Care (AM-PAC) "6 Clicks" Basic Mobility Inpatient Short Form score from baseline to discharge. Target: improvement of ≥2 points. Score range 6-24, with higher scores indicating better mobility function.
Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
Change in AM-PAC 6-Clicks Activities of Daily Living Score
Time Frame: Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
Change in Activity Measure for Post-Acute Care (AM-PAC) "6 Clicks" Activities of Daily Living (ADL) Inpatient Short Form score from baseline to discharge. Score range 6-24, with higher scores indicating better ADL function.
Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
Discharge Disposition to Home
Time Frame: At hospital discharge, approximately 5-7 days after admission
Percentage of participants discharged directly home (versus inpatient rehabilitation facility, skilled nursing facility, long-term acute care hospital, or death). Target: increase of ≥7% compared to 2025 unit-specific historical rate.
At hospital discharge, approximately 5-7 days after admission
Incidence of Hospital-Acquired Weakness
Time Frame: At hospital discharge, approximately 5-7 days after admission
Percentage of participants with hospital-acquired weakness defined as Medical Research Council (MRC) sum score <48 at discharge. MRC sum score assesses strength in 12 muscle groups bilaterally (range 0-60), with scores <48 indicating clinically significant weakness. Target incidence: <30%.
At hospital discharge, approximately 5-7 days after admission
New Institutionalization at 60 Days Post-Discharge
Time Frame: 60 days post-hospital discharge
Percentage of participants requiring new placement in skilled nursing facility, long-term care facility, or inpatient rehabilitation facility at 60 days post-discharge (among those discharged home initially).
60 days post-hospital discharge
Change in One-Minute Sit-to-Stand Repetitions
Time Frame: Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
Change in number of sit-to-stand repetitions completed in one minute from baseline to discharge. This test measures lower extremity strength and functional capacity.
Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
Change in Six-Minute Walk Test Distance
Time Frame: Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
Change in distance walked in six minutes from baseline to discharge, measured in meters. This test assesses cardiorespiratory fitness and functional exercise capacity.
Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
Change in EQ-5D Quality of Life Score
Time Frame: Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
Change in EQ-5D (EuroQol 5-Dimension) health-related quality of life score from baseline to discharge. The EQ-5D assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
Change in Hospital Anxiety and Depression Scale (HADS)
Time Frame: Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
Change in HADS total score from baseline to discharge. HADS consists of anxiety and depression subscales (each 0-21, total 0-42), with higher scores indicating greater symptom severity.
Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
Change in Berg Balance Scale Score
Time Frame: Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
Change in Berg Balance Scale score from baseline to discharge. Scale ranges 0-56, with higher scores indicating better balance. Scores <45 indicate higher fall risk.
Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
Change in Timed Up and Go Test Duration
Time Frame: Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
Change in time (seconds) required to stand from a chair, walk 3 meters, turn around, walk back, and sit down from baseline to discharge. Shorter times indicate better functional mobility.
Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
Change in Quadriceps Isometric Strength
Time Frame: Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
Change in quadriceps muscle strength measured via handheld dynamometry from baseline to discharge, measured in kilograms of force or Newtons.
Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
Change in Johns Hopkins Highest Level of Mobility (JH-HLM) Score
Time Frame: Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
Change in JH-HLM score from baseline to discharge. Scale ranges 1-8, with higher scores indicating greater mobility independence (1=lying in bed to 8=ambulating >250 feet).
Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
Change in Estimated VO2 Max
Time Frame: Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
Change in estimated maximal oxygen consumption (VO2 max) from baseline to discharge, measured in mL/kg/min. VO2 max indicates cardiorespiratory fitness.
Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
Change in Braden Skin Score
Time Frame: Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
Change in Braden Scale for Predicting Pressure Sore Risk from baseline to discharge. Scale ranges 6-23, with lower scores indicating higher risk for pressure ulcer development.
Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
Change in Morse Fall Scale Score
Time Frame: Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
Change in Morse Fall Scale score from baseline to discharge. Scale ranges 0-125, with higher scores indicating greater fall risk (0-24=low risk, 25-50=moderate risk, ≥51=high risk).
Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
60-Day Hospital Readmission Rate
Time Frame: 60 days post-hospital discharge
Percentage of participants readmitted to any hospital within 60 days of discharge from index hospitalization, assessed via medical record review.
60 days post-hospital discharge
Incidence of Falls Within 60 Days Post-Discharge
Time Frame: 60 days post-hospital discharge
Number and percentage of participants experiencing one or more falls after hospital discharge, occurring in any setting (home, post-acute care facility, or community), assessed via medical record review and telephone follow-up.
60 days post-hospital discharge
60-Day All-Cause Mortality
Time Frame: 60 days post-hospital discharge
All-cause mortality within 60 days of hospital discharge, assessed via medical record review and telephone follow-up.
60 days post-hospital discharge
Living Setting at 60 Days Post-Discharge
Time Frame: 60 days post-hospital discharge
Participant's living arrangement at 60 days post-discharge, categorized as: home (independent), home (with assistance), skilled nursing facility, long-term care facility, inpatient rehabilitation, other, or deceased.
60 days post-hospital discharge
Total Healthcare Costs Through 60 Days
Time Frame: From hospital admission through 60 days post-discharge (approximately 65-75 days total)
Total direct healthcare costs including index hospitalization and all healthcare utilization within 60 days post-discharge, obtained from de-identified aggregated claims data. Costs measured in US dollars.
From hospital admission through 60 days post-discharge (approximately 65-75 days total)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Chris Gales, DPT, Indiana University
  • Principal Investigator: Babar Khan, MD, Indiana University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

July 5, 2026

Primary Completion (Estimated)

September 30, 2026

Study Completion (Estimated)

December 31, 2026

Study Registration Dates

First Submitted

December 4, 2025

First Submitted That Met QC Criteria

December 4, 2025

First Posted (Actual)

December 15, 2025

Study Record Updates

Last Update Posted (Actual)

March 27, 2026

Last Update Submitted That Met QC Criteria

March 24, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Delirium

Clinical Trials on Bedside Bike

Subscribe